|
 Valneva said its facility in Lyon, central France, had succeeded in
generating a "highly purified inactivated vaccine candidate" using
the same platform as the company's Japanese encephalitis vaccine
which is marketed in the United States and Europe.
No other details were immediately available.
France's Sanofi is the only major drugmaker working on a vaccine
against Zika, which has been linked to birth defects and
neurological disorders, although more than a dozen smaller biotech
firms and other groups are also active in the field.
Valneva said in the statement that subject to regulatory approval,
it could be in a position to conduct clinical investigations in the
coming months.
Global health officials are racing to better understand the Zika
virus, which has caused a major outbreak that began in Brazil last
year and has spread to many countries in the Americas.
(Reporting by Matthias Blamont; Editing by Richard Lough and
Alexandra Hudson)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
